Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing - 2Moldova says Russian drones violated airspace
- 3The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- 4Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- 5vote in favor of Your #1 kind of climate
- Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- 'I was diagnosed with incurable brain cancer on holiday'
- Figure out How to Stay away from Normal Handshaking Missteps
- 'Harmonious' meeting between Merz, Lula despite Belém controversy
- UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- Knesset sets special panel to fast-track Karhi’s communications reform
- New Jordan security fence could be done in early 2028
- Early diagnosis leads King Charles to scale back cancer treatment in the new year
